1[1]Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone[J]. Clin Infect Dis, 2000, 31(Suppl 2): S51-58
2[2]Perry CM, Ormrod D, Hurst M, et al. Gatifloxacin: a review of its use in the management of bacterial infections[J]. Drugs, 2002, 62: 169-207
3[3]Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults[J]. Clin Infect Dis, 2000, 31: 347-382
4[4]Niederman MS, Momdell CA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention[J]. Am J Respir Crit Care Med, 2001, 163: 1730-1754
5[5]Pankuch GA, Jacobs MR, Appelbaum PC. Postantibiotic effects of gatifloxacin against Gram-positive and negative organisms[J]. Antimicrob Agents Chemother, 1999, 43: 2574-2575
6[6]Sullivan JG, McElroy AD, Honsinger RW, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin[J]. J Respir Dis, 1999, 20(suppl): S49-S59
7[7]Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone[J]. J Respir Dis, 1999, 20(suppl): s70-s75
